CAPRICOR THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.2 USD | +10.32% |
|
+16.98% | +26.79% |
| May. 17 | Oppenheimer Initiates Capricor Therapeutics at Outperform Rating | MT |
| May. 13 | Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024 |
Evolution of the average Target Price on Capricor Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
b1f1d07263952917a1.kSHjAeeX3wVAX49gkS_pq9PkJGq_G1bxQdmCrbK1vDs.-VWRNZf1hXQXF9A_xESc5OS7UBjlQmG4Nb7m7NTjjmn8bZtChcGwXA9qzg~50e46972584bdf0a22044a5f0b54445d
More recommendations
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.2
USD
Average target price
19.8
USD
Spread / Average Target
+219.35%
High Price Target
40
USD
Spread / Highest target
+545.16%
Low Price Target
8
USD
Spread / Lowest Target
+29.03%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Capricor Therapeutics, Inc.
| Oppenheimer | |
| HC Wainwright | |
| Ladenburg Thalmann |
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
- Stock Market
- Equities
- CAPR Stock
- Consensus Capricor Therapeutics, Inc.
